Arrowgrass Capital Partners (US)’s AstraZeneca AZN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-55,727	Closed	-$3.98M	–	426
2014 Q3	$3.98M	Sell	55,727 -87,162	-61%	-$6.38M	0.1%	127
2014 Q2	$10.6M	Buy	+142,889	New	+$10.3M	0.31%	63
2014 Q1	–	Sell	-238,489	Closed	-$14.2M	–	166
2013 Q4	$14.2M	Sell	238,489 -270,713	-53%	-$14.7M	0.67%	40
2013 Q3	$26.4M	Buy	+509,202	New	+$25.6M	0.99%	24

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s AZN Position: Q4 2014 in Review

Arrowgrass Capital Partners (US) sold out of AstraZeneca (AZN) in Q4 2014, closing a stake of 55,727 shares — an estimated $3.98M sold.

Arrowgrass Capital Partners (US) first reported a position in AZN in Q3 2013 and held it in 4 quarters. The position peaked at $26.4M in Q3 2013. 404 funds tracked by Wall St. Rank hold AZN as of Q4 2014.

Arrowgrass Capital Partners (US) reported no remaining AstraZeneca position as of Q4 2014 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 55,727 AstraZeneca shares in Q4 2014, an estimated $3.98M.
Arrowgrass Capital Partners (US) first reported a position in AstraZeneca in Q3 2013 and held it in 4 quarters.
Arrowgrass Capital Partners (US)'s AstraZeneca position peaked at $26.4M in Q3 2013.
404 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2014.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2014, filed 18 Feb 2015.